What it's for (Indications)
- Antithymocyte globulin (rabbit), such as Thymoglobuline, is a potent immunosuppressive agent indicated for various conditions requiring significant T-cell depletion and immunomodulation.
- Its primary uses include the treatment of acute moderate to severe renal allograft rejection refractory to conventional therapy.
- Furthermore, it is approved for the prevention of acute rejection in kidney transplant recipients, often as part of an induction regimen.
- In hematology, it is crucial for the treatment of moderate to severe aplastic anemia in patients who are not candidates for hematopoietic stem cell transplantation or for whom no suitable donor is available.
- It is also utilized in conditioning regimens for hematopoietic stem cell transplantation to prevent graft-versus-host disease and for the treatment of steroid-refractory acute graft-versus-host disease.
- This broad application underscores its critical role in managing severe immunological disorders and preventing transplant rejection.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of antithymocyte globulin (rabbit) is highly individualized based on the specific indication, patient weight, and clinical response, and it is administered via slow intravenous infusion into a high-flow vein after dilution in saline or dextrose solutions. For the treatment of acute renal transplant rejection, typical doses range from 1.5 mg/kg/day for 7 to 14 days, tailored to clinical and immunological parameters. For aplastic anemia, regimens commonly involve 3.5 mg/kg/day for 5 days. For induction therapy in kidney transplantation, doses typically range from 1.5 mg/kg/day for 3 to 7 days. Premedication with corticosteroids (e.g., methylprednisolone), antihistamines (e.g., diphenhydramine), and antipyretics (e.g., acetaminophen) is mandatory prior to the first dose and often for subsequent doses to mitigate infusion-related reactions. Close monitoring of hematological parameters, particularly leukocyte (specifically lymphocyte) and platelet counts, is essential throughout treatment to guide dose adjustments or temporary interruptions, ensuring patient safety and efficacy. |
Safety & Warnings
Common Side Effects
- Antithymocyte globulin therapy is associated with a broad spectrum of adverse effects, ranging from common infusion-related reactions to severe infectious and oncologic complications.
- Immediate infusion-related reactions, often termed cytokine release syndrome, are prevalent and can manifest as fever, chills, rigors, headache, nausea, vomiting, diarrhea, hypotension, dyspnea, and rash, typically occurring during or shortly after the first few doses.
- These reactions are managed with premedication and careful infusion rate adjustments.
- Hematologic toxicities, including profound leukopenia (lymphopenia and neutropenia) and thrombocytopenia, are expected given the mechanism of action, necessitating frequent blood count monitoring and potential dose modification or interruption.
- Due to its potent immunosuppressive nature, patients are at a significantly increased risk for opportunistic infections (e.
- g.
- , cytomegalovirus, Epstein-Barr virus, fungal, bacterial, viral hepatitis reactivation) and the development of post-transplant lymphoproliferative disorder (PTLD) or other malignancies, particularly skin cancers.
- Anaphylaxis and serum sickness are rare but serious hypersensitivity reactions, requiring immediate medical intervention.
- Other adverse effects may include gastrointestinal disturbances, arthralgia, and myalgia.
Serious Warnings
- Black Box Warning: **WARNING: RISK OF SERIOUS INFECTIONS, MALIGNANCY, AND SEVERE HYPERSENSITIVITY REACTIONS** Antithymocyte globulin (rabbit) carries a substantial risk of profound and prolonged immunosuppression, which can lead to life-threatening or fatal infections. Patients are highly susceptible to opportunistic infections, including but not limited to bacterial, viral (e.g., cytomegalovirus, Epstein-Barr virus, BK virus, herpes simplex, varicella zoster), fungal, and protozoal infections. Prophylactic antimicrobial therapy is often essential and should be considered based on clinical guidelines, institutional protocols, and individual patient risk factors. Due to its potent immunosuppressive effects, there is an increased risk of developing malignancies, particularly post-transplant lymphoproliferative disorder (PTLD), which is frequently associated with Epstein-Barr virus infection and can be fatal, as well as other solid organ malignancies and skin cancers. Vigilant monitoring for signs and symptoms of infection and malignancy is critical throughout and following treatment. Furthermore, severe systemic hypersensitivity reactions, including anaphylaxis, have been reported and can be life-threatening. These reactions typically occur during or after the first or second infusion. Epinephrine and other resuscitative measures, along with a facility equipped for managing anaphylaxis, must be immediately available for prompt intervention. Infusion-related reactions, including cytokine release syndrome, are also common and can be severe; careful premedication with corticosteroids, antihistamines, and antipyretics is required to mitigate these effects.
- Patients receiving antithymocyte globulin are at substantial risk for severe adverse events requiring careful management and close monitoring.
- Profound immunosuppression increases susceptibility to life-threatening or fatal infections, including bacterial, viral (e.
- g.
- , CMV, EBV, adenovirus, BK virus), fungal, and protozoal pathogens; prophylactic anti-infective regimens are frequently necessary and should be guided by institutional protocols and patient-specific risk factors.
- The risk of malignancy, particularly post-transplant lymphoproliferative disorder (PTLD), which is often EBV-associated, is elevated; vigilant surveillance for signs and symptoms of infection and malignancy is critical throughout and following treatment.
- Acute systemic hypersensitivity reactions, including anaphylaxis, can occur, particularly with initial doses; epinephrine and other resuscitative measures should be readily available, and infusions should be administered in a setting equipped for managing such emergencies.
- Infusion-related reactions, often a manifestation of cytokine release syndrome, can be severe and necessitate careful premedication, slow infusion rates, and potentially temporary cessation of infusion.
- Hematologic toxicities such as profound leukopenia (lymphopenia and neutropenia) and thrombocytopenia are common and require dose adjustment or interruption based on frequent blood count monitoring.
- Live attenuated vaccines are contraindicated during treatment and for a period thereafter due to the risk of vaccine-induced infection.
- Pregnancy and lactation considerations demand careful risk-benefit assessment due to potential fetal harm (category C) and unknown excretion into breast milk; effective contraception is advised for women of childbearing potential during and for a period after therapy.
How it Works (Mechanism of Action)
Antithymocyte globulin (rabbit), derived from the immunization of rabbits with human thymocytes, functions as a polyclonal antibody preparation. Its primary mechanism of action involves the profound depletion of T-lymphocytes, which are central to cellular immunity and play a critical role in allograft rejection and autoimmune processes. The immunoglobulin preparation contains a diverse array of antibodies that recognize and bind to multiple T-cell surface antigens, including but not limited to CD2, CD3, CD4, CD8, CD11a, CD18, CD44, CD45, CD58, HLA-DR, and beta-2 microglobulin. This binding initiates the destruction of T-cells primarily through complement-dependent lysis and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as opsonization followed by phagocytosis in the reticuloendothelial system (e.g., spleen, liver). In addition to direct T-cell depletion, antithymocyte globulin also possesses significant immunomodulatory properties, affecting lymphocyte function, adhesion molecule expression, and migration. This multifaceted action results in a significant and rapid reduction in the number of circulating T-lymphocytes, thereby effectively attenuating the immune response and preventing or treating immune-mediated conditions such as transplant rejection, aplastic anemia, and graft-versus-host disease.
Commercial Brands (Alternatives)
No other brands found for this formula.